Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women

Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.

Saved in:
Bibliographic Details
Published inP&T (Lawrenceville, N.J.) Vol. 42; no. 4; pp. 237 - 241
Main Authors English, Clayton, Muhleisen, Anne, Rey, Jose A
Format Journal Article
LanguageEnglish
Published United States MediMedia USA, Inc 01.04.2017
Subjects
Departments
Online AccessGet full text

Cover

More Information
Summary:Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Dr. English is an Associate Professor in the Department of Pharmacy Practice at Albany College of Pharmacy and Health Sciences in Colchester, Vermont. Dr. Muhleisen is a pharmacist at Arizona Spine and Joint Hospital in Mesa, Arizona. Dr. Rey is Director of the Psychopharmacology Residency Program and Associate Professor in the Department of Pharmacy Practice at Nova Southeastern University College of Pharmacy in Fort Lauderdale, Florida. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi and Associates in New York, New York.
ISSN:1052-1372